Identification of DNA-PKcs as a primary resistance factor of salinomycin in osteosarcoma cells

Oncotarget. 2016 Nov 29;7(48):79417-79427. doi: 10.18632/oncotarget.12712.

Abstract

Malignant osteosarcoma (OS) is still a deadly disease for many affected patients. The search for the novel anti-OS agent is extremely urgent and important. Our previous study has proposed that salinomycin is a novel anti-OS agent. Here we characterized DNA-dependent protein kinase catalytic subunit (DNA-PKcs) as a primary salinomycin resistance factor in OS cells. DNA-PKcs inhibitors (NU7026, NU7441 and LY294002) or DNA-PKcs shRNA knockdown dramatically potentiated salinomycin-induced death and apoptosis of OS cells (U2OS and MG-63 lines). Further, forced-expression of microRNA-101 ("miR-101") downregulated DNA-PKcs and augmented salinomycin's cytotoxicity against OS cells. Reversely, over-expression of DNA-PKcs in OS cells inhibited salinomycin's lethality. For the mechanism study, we show that DNA-PKcs is required for salinomycin-induced pro-survival autophagy activation. DNA-PKcs inhibition (by NU7441), shRNA knockdown or miR-101 expression inhibited salinomycin-induced Beclin-1 expression and autophagy induction. Meanwhile, knockdown of Beclin-1 by shRNA significantly sensitized salinomycin-induced OS cell lethality. In vivo, salinomycin administration suppressed U2OS xenograft tumor growth in severe combined immuno-deficient (SCID) mice, and its anti-tumor activity was dramatically potentiated with co-administration of the DNA-PKcs inhibitor NU7026. Together, these results suggest that DNA-PKcs could be a primary resistance factor of salinomycin in OS cells. DNA-PKcs inhibition or silence may thus significantly increase salinomycin's sensitivity in OS cells.

Keywords: DNA-PKcs; autophagy; microRNA-101; osteosarcoma (OS); salinomycin.

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / pharmacology
  • Bone Neoplasms / genetics
  • Bone Neoplasms / metabolism*
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Cell Survival / drug effects
  • Chromones / administration & dosage*
  • Chromones / pharmacology
  • DNA-Activated Protein Kinase / genetics*
  • DNA-Activated Protein Kinase / metabolism
  • Drug Resistance, Neoplasm* / drug effects
  • Drug Synergism
  • Humans
  • Mice
  • MicroRNAs / genetics
  • Morpholines / administration & dosage*
  • Morpholines / pharmacology
  • Neoplasm Transplantation
  • Nuclear Proteins / genetics*
  • Nuclear Proteins / metabolism
  • Osteosarcoma / genetics
  • Osteosarcoma / metabolism*
  • Pyrans / administration & dosage*
  • Pyrans / pharmacology

Substances

  • 2-(morpholin-4-yl)benzo(h)chromen-4-one
  • Antineoplastic Agents
  • Chromones
  • MIRN101 microRNA, human
  • MicroRNAs
  • Morpholines
  • Nuclear Proteins
  • Pyrans
  • salinomycin
  • DNA-Activated Protein Kinase
  • PRKDC protein, human